Abstracts tagged "Systemic sclerosis"

Abstract Number: 1704 • ACR Convergence 2023
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
gerlando Natalello¹, enrico De Lorenzis¹, Ludovica Berardini², lucrezia verardi¹, pier giacomo Cerasuolo¹, Alfredo Papa³, Italo De Vitis³, Francesco Varone², Luca Richeldi², Maria Antonietta D'Agostino¹ and Silvia Bosello¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ³Division of Gastroenterology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…
Abstract Number: 2366 • ACR Convergence 2023
Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Hung Vo¹, Aarohi Mehendale², Anahita Pilvar³, Eugene Kissin⁴, Marcin Trojanowski⁵, Michael York⁶, Darren Roblyer² and Andreea Bujor⁶, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Department of Electrical and Computer Engineering, Boston University, Boston, MA, ⁴Boston University, Newton, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…
Abstract Number: 0619 • ACR Convergence 2023
Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review
liubov Petelytska¹, Francesco Bonomi², Carlo Cannistrà³, elisa Fiorentini⁴, Silvia Peretti³, Sara Torracchi³, Pamela Bernardini³, Carmela Coccia³, Riccardo De Luca³, Alessio Economou³, Juela Levani⁵, marco Matucci Cerinic⁶, Oliver Distler⁷ and Cosimo Bruni⁷, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²University of Florence, Firenze, Italy, ³University of Florence, Florence, Italy, ⁴Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, ⁵Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ⁶Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: There is no established consensus on defining the clinical course and the outcomes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), both among experts and…
Abstract Number: 0637 • ACR Convergence 2023
Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Hilde Jenssen Bjørkekjær¹, Cosimo Bruni², Cathrine Brunborg³, Patricia Carreira⁴, Paolo Airò⁵, Carmen Pilar Simeon-Aznar⁶, Marie-Elise Truchetet⁷, Alessandro Giollo⁸, Alexandra Balbir-Gurman⁹, Mickael Martin¹⁰, Christopher Denton¹¹, Armando Gabrielli¹², Havard Fretheim¹³, Imon Barua¹³, Helle Bitter¹⁴, Oyvind Midtvedt¹³, Torhild Garen¹⁵, Kaspar Broch¹⁶, Arne Andreassen¹⁷, Yoshiya Tanaka¹⁸, Gabriela Riemekasten¹⁹, Ulf Müller-Ladner²⁰, marco Matucci Cerinic²¹, Ivan Castellvi²², Elise Siegert²³, Eric Hachulla²⁴, Oliver Distler² and Anna-Maria Hoffmann-Vold¹³, ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁶Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ¹¹University College London, London, United Kingdom, ¹²Ospedali Riuniti Marche, Ancona, Italy, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Sorlandet sykehus, Kristiansand, Norway, ¹⁵Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ¹⁶Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, ¹⁷Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, ¹⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ²⁰Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²²Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ²³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ²⁴University of Lille, Lille, France
Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…
Abstract Number: 0659 • ACR Convergence 2023
Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort
Jacopo Ciaffi¹, Sophie Liem², Saad Ahmed², Eva Hoekstra², Piotr Wiland³, Tatsuya Atsuma⁴, Gabriella Szucs⁵, Alexandra Balbir-Gurman⁶, Laszlo Czirjak⁷, Elisabetta Zanatta⁸, Ina Koetter⁹, Joerg Henes¹⁰, marco Matucci Cerinic¹¹, Paolo Airò¹², Francesco Ursini¹³, Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Wroclaw University of Medicine, Wroclaw, Poland, ⁴Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁵University of Debrecen, Department of Rheumatology, Debrecen, Hungary, ⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁷Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ⁹University Hospital Eppendorf, Prisdorf, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany, ¹¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹²Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹³IRCCS Istituto Ortopedico Rizzoli, Bologna, Netherlands
Background/Purpose: In rheumatoid arthritis, cigarette smoking confers a risk for anti-CCP positive disease and the risk further increases in smokers carrying specific HLA DRB1-variants. These…
Abstract Number: 0934 • ACR Convergence 2023
Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis
Hiroshi Matsuura¹, Masahiro Kondo¹, Ryoko Ohno¹, Akina Ishii¹, Mariam Piruzyan¹, Kaori Funayama¹, Yuuichi Ono¹, Atsushi Iwamura¹, Tadashi Endo¹, Tomoya Akashi¹, Taizo Tomari², Noriko Uchiyama², Noriyasu Seki¹, Kenji Chiba¹, Gabriela Kania³, Przemyslaw Blyszczuk⁴, Oliver Distler⁵, Tsutomu Takeuchi⁶ and Yuko Kaneko⁷, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Japan, ³University of Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Targeted small-molecule therapies to autotaxin (ATX), the lysophosphatidic acid (LPA)-producing enzyme, have been shown to be potentially effective in systemic sclerosis (SSc), but the…
Abstract Number: 0956 • ACR Convergence 2023
Effects of B Cell Depletion by CD19-targeted CAR-T Cells in a Murine Model of Systemic Sclerosis
Jérôme Avouac¹, Anne Cauvet², Cindy Orvain³, Morgane boulch⁴, Philippe Bousso⁴ and Yannick ALLANORE⁵, ¹Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ²INSERM U1016, Paris, France, ³INSERM U1016, Paris, ⁴Institut Pasteur, Paris, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: Chimeric antigen receptor (CAR)-T cells represent a potentially curative strategy for B cell malignancies. A first successful clinical experience has been recently reported in…
Abstract Number: 1523 • ACR Convergence 2023
The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis
Muruganandam Maheswari, Eyerusalem Akpan, Matthew Mcelwee, Meredith Keller, Angie Ariza - Hutchinson, Rosemina Patel, Wilmer Sibbitt, Frank O'Sullivan, Sharon nunez, N. Suzanne Emil and Roderick Fields, University of New Mexico, Albuquerque, NM
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but a life-threatening complication of systemic sclerosis (SSc), affecting 2-15% of patients with SSc. SRC has been…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 2369 • ACR Convergence 2023
Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients
Hadijat Makinde¹, Matthew Dapas², Salina Dominguez², Tyler Therron¹, Miranda Gurra¹, Mary Karns³, Kathleen Aren³, Alexandra Soriano², Lutfiyya Muhammad⁴, Carla Cuda¹, Dustin Carlson¹, Jane Dematte⁵, Darren Brenner¹, John Pandolfino⁶, Harris Perlman¹, Deborah Winter⁷ and Marie-Pier Tetreault¹, ¹Northwestern University, Chicago, IL, ²Northwestern University FSM Division of Rheumatology, Chicago, IL, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Elmhurst, IL, ⁶Northwestern University, Feinberg School of Medicine, Wilmette, IL, ⁷Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with Gastroesophageal Reflux Disease (GERD),…
Abstract Number: 0046 • ACR Convergence 2023
Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles
Kieran Woolcock¹, Nila Servaas², Maarten van der Kroef², Stephen Delaney³, John Cole¹, Aridaman Pandit² and Carl Goodyear¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University Medical Center Utrecht and Utrecht University, Utrecht, Netherlands, ³Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), and Systemic sclerosis (SSc) are all systemic rheumatic autoimmune diseases with a dysregulated myeloid compartment. Monocytes are…
Abstract Number: 0620 • ACR Convergence 2023
Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry
Isha Lamba¹, Ashima Makol², Dinesh Khanna³, John VanBuren⁴, Angela Child⁴, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Kimberly Lakin¹³, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Carrie Richardson¹⁸, Nora Sandorfi¹⁹, Ami Shah²⁰, Ankoor Shah²¹, Victoria Shanmugam²², Brian Skaug²³, Virginia Steen²⁴, Elizabeth Volkmann²⁵ and Jessica Gordon¹³, ¹New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of Michigan, Ann Arbor, MI, ⁴University of Utah, Salt Lake City, UT, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³Hospital for Special Surgery, New York, NY, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern Memorial Hospital, Chicago, IL, ¹⁸Northwestern University, Riverside, IL, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²¹Duke University, Durham, NC, ²²Victoria Shanmugam, MD, Great Falls, VA, ²³Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Patient-Reported Outcomes Measurement Information System-29 version 2.0 (PROMIS-29v2) is a patient-centered questionnaire used to assess health-related quality of life (HRQoL). PROMIS-29v2 has shown validity…
Abstract Number: 0640 • ACR Convergence 2023
Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis
Marco Di Battista¹, Alessandra Rossi¹, Gaia Pisano¹, Riccardo Morganti², Alessandra Della Rossa³ and Marta Mosca⁴, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Section of Statistics, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease with a heterogeneous clinical expression that heavily affects the functionality and quality of life of patients.…
Abstract Number: 0660 • ACR Convergence 2023
Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort
Jacopo Ciaffi¹, Sophie Liem², Saad Ahmed², Eva Hoekstra², Piotr Wiland³, Tatsuya Atsuma⁴, Gabriella Szucs⁵, Alexandra Balbir-Gurman⁶, Laszlo Czirjak⁷, Elisabetta Zanatta⁸, Ina Koetter⁹, Joerg Henes¹⁰, marco Matucci Cerinic¹¹, Paolo Airò¹², Francesco Ursini¹³, Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Wroclaw University of Medicine, Wroclaw, Poland, ⁴Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁵University of Debrecen, Department of Rheumatology, Debrecen, Hungary, ⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁷Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ⁹University Hospital Eppendorf, Prisdorf, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany, ¹¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹²Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹³IRCCS Istituto Ortopedico Rizzoli, Bologna, Netherlands
Background/Purpose: Cigarette smoking is an established risk factor for mortality in the general population but, in systemic sclerosis (SSc), evidence about the role of smoking…
Abstract Number: 0936 • ACR Convergence 2023
Impaired DNA Repair Responses Activate a Novel FOXO1-dependent Metabolic Remodelling in Patients with Progressive Systemic Sclerosis to Promote Fibrosis
Lamia Khan, Desiree Redmond, Muhammad Elezzabi, Robert Gniadecki, Jan Willem Cohen Tervaert and Mohamed Osman, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a deadly disease characterized by immune dysregulation, vasculopathy, and fibrosis. SSc is the most lethal rheumatic disease associated with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].